Moderna (NASDAQ:MRNA – Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Profitability
This table compares Moderna and Dianthus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Moderna | -143.55% | -26.64% | -19.32% |
| Dianthus Therapeutics | -12,998.50% | -27.30% | -25.91% |
Institutional and Insider Ownership
75.3% of Moderna shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Moderna | 5 | 11 | 2 | 0 | 1.83 |
| Dianthus Therapeutics | 1 | 0 | 12 | 1 | 2.93 |
Moderna presently has a consensus price target of $36.60, suggesting a potential downside of 26.67%. Dianthus Therapeutics has a consensus price target of $117.82, suggesting a potential upside of 43.56%. Given Dianthus Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Moderna.
Earnings and Valuation
This table compares Moderna and Dianthus Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Moderna | $1.94 billion | 10.19 | -$2.82 billion | ($8.15) | -6.12 |
| Dianthus Therapeutics | $1.34 million | 3,358.11 | -$162.34 million | ($4.13) | -19.87 |
Dianthus Therapeutics has lower revenue, but higher earnings than Moderna. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.
Summary
Dianthus Therapeutics beats Moderna on 8 of the 15 factors compared between the two stocks.
About Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
